DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20221048

Molnupiravir: a new hope in the treatment of COVID-19

Rama Paudel

Abstract


Coronavirus disease-19 (COVID-19), a highly contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been causing pandemic since its first emergence in Wuhan, China in December 2019.1 Most of the people with COVID-19 experience mild to moderate respiratory illness and recover without requiring special treatment. The common presentations of the disease include fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting and diarrhea.2 However, upto 20% patients develop severe disease requiring hospitalization.3 Older adults and people with underlying medical conditions like heart or lung disease or diabetes are at higher risk for developing more serious complications such as pneumonia, acute respiratory distress syndrome, cardiac injury, arrhythmia, septic shock, liver dysfunction, acute kidney injury, multi-organ failure and death of the patients.2,4 The pandemic has presented a major threat to public health worldwide. As of 13 March 2022, World Health Organization (WHO) reported a total of 452,201,564 confirmed cases of COVID-19 with 6,029,852 deaths (case fatality: 1.33%).5


Keywords


COVID-19, WHO, SARS-CoV-2

Full Text:

PDF

References


Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new Coronavirus of probable bat origin. Nature. 2020;579:270-3.

Center for Disease control and prevention (CDC). Symptoms of COVID-19. Available at: https://www.cdc.gov/coronavirus/2019-ncov/sym ptoms-testing/symptoms.html. Accessed on 14 March 2022.

Anesi GL. COVID-19: epidemiology, clinical features, and prognosis of the critically ill adult. Available at: https://www.uptodate.com/contents /covid-19-epidemiology-clinical-features-and-prognosis-of-the-critically-ill-adult. Accessed on 12 March 2022.

Cennimo DJ. Coronavirus disease 2019 (COVID-19). Available at: https://emedicine.medsca pe.com/article/2500114-overview. Accessed on 13 March 2022.

World Health Organization (WHO). Coronavirus (COVID-19) dashboard. Available at: https://covid19.who.int/. Accessed on 14 March 2022.

World Health Organization (WHO). WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access. Available at: https://www.who.int/news /item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access. Accessed on 13 March 2022.

Global Alliance for Vaccines and Immunization (Gavi). The COVID-19 vaccine race – weekly update. Available at: https://www.gavi.org/vaccineswork /covid-19-vaccine-race. Accessed on 14 March 2022.

Pourkarim F, Pourtaghi-Anvarian S, Rezaee H. Molnupiravir: A new candidate for COVID-19 treatment. Pharmacol Res Perspect. 2022;10:e00909.

US Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee. Molnupiravir. Available at: https://www.fda.gov /media/154472/download. Accessed on 13 March 2022.

US Food and Drug Administration (FDA). Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19. Available at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19. Accessed on 13 March 2022.

US Food and Drug Administration (FDA). Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults. Available at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain#:~:text=Today%2C%20the%20U.S.%20Food%20and,progression%20to%20severe%20COVID%2D19%2C. Accessed on 13 March 2022.

National Institutes of Health (NIH). COVID-19 Treatment guidelines. Molnupiravir: Available at: https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/molnupiravir/. Accessed on 13 March 2022.

Bernal AJ, Silva GD, Musungaie DB, Kovalchuk E, Gonzlez A, Reyes VD, et al. Molnupiravir for oral treatment of COVID-19 in non-hospitalized patients. N Engl J Med. 2022;386(6):509-20.

US Food and Drug Administration (FDA). Fact sheet for healthcare providers: emergency use authorization for molnupiravir. 2021. Available at: https://www.fda.gov/media/155054/download. Accessed on 14 March 2022.

World Health Organization (WHO). WHO updates its treatment guidelines to include molnupiravir. Available at: https://www.who.int/news/item/03-03-2022-molnupiravir. Accessed on 14 March 2022.